LEPTIN TREATMENT IN HIV-1 PROTEASE INHIBITOR-INDUCED LIPODYSTROPHY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 包括HIV-1蛋白酶抑制剂（PI）的高效抗逆转录病毒疗法（HAART）大大降低了HIV相关死亡率。 然而，这些患者中的许多发展为脂肪营养不良，其特征在于身体脂肪的重新分布和胰岛素抵抗。 在5- 70%接受含PI方案治疗的患者中观察到高甘油三酯血症和葡萄糖耐量受损。 低瘦素水平也已报告在这些患者中的一些选择性损失的皮下脂肪组织。 我们最近证明了瘦素替代疗法在非HIV感染的其他遗传性和获得性脂肪营养不良患者中的疗效。 本研究的目的是探讨瘦素治疗HAART相关脂肪代谢障碍患者的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Highly Active Anti-Retroviral Therapies (HAART) that include HIV-1 protease inhibitors (PI) have greatly reduced HIV related mortality rates. However, many of these patients develop lipodystrophy, characterized by redistribution of body fat and insulin resistance. Hypertriglyceridemia and impaired glucose tolerance has been noted in 5- to 70% of patients treated with PI containing regimens. Low leptin levels have also been reported in some of these patients with selective loss of subcutaneous adipose tissue. We have recently demonstrated the efficacy of leptin replacement therapy in non HIV-infected patients with other genetic and acquired lipodystrophies. The purpose of this study is to investigate the safety and efficacy of leptin therapy in patients with HAART associated lipodystrophy.